Maddocks

A former director of marketing companies linked to the failed Shield and First Guardian funds says ASIC's 14-month investigation has left him facing a travel ban and freezing orders but no substantive allegations.

A Western Sydney council has lost its bid to keep expert evidence in an arbitration with a builder under wraps in its $7 million case alleging a Sydney architect is liable for defects in a tennis court complex. 

Builder Watpac has lost its bid for a separate hearing on whether a guarantee provided to the developer of Sydney's One Central Park is time-barred, with a judge saying the question should wait until $180 million in defects claims are determined.

Bentleys Wealth is suing a former director and his companies alleging he poached clients after leaving the firm, in breach of his employment agreement and various duties. 

AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege. 

Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.

German car hire company SIXT has attacked the Darwin International airport owner's construction of their lease contract in a $1.9 million spat over the appropriate formula for rent calculations, saying it was trying to have the "best of both worlds".

A court has signed off on Someva Renewables' plan to build 62 wind turbines just outside of Hanging Rock following what the company called 18 months of "unnecessary" opposition from a local council that did little to alter the project. 

A judge has approved orders bringing the receivership of Banksia Securities to an end, with the special receiver opting to not pursue $650,000 in costs against Victorian debenture holders who dropped their case alleging breaches to the scandal-ridden class action.

Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.